LONDON: Ondine Biomedical Inc., a Canadian life sciences company listed on AIM (OBI), has announced a significant fundraising effort to secure at least £3 million (C$5.15 million) from mainly existing shareholders. The initiative includes a placement and a subscription, aiming to issue over 43 million new common shares at 7 pence each, a 36.6% premium…